<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00460</drugbank-id>
  <drugbank-id>APRD01290</drugbank-id>
  <name>Verteporfin</name>
  <description>Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.</description>
  <cas-number>129497-78-5</cas-number>
  <unii>0X9PA28K43</unii>
  <average-mass>718.7942</average-mass>
  <monoisotopic-mass>718.30026434</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A691</ref-id>
        <pubmed-id>20162298</pubmed-id>
        <citation>Chan WM, Lim TH, Pece A, Silva R, Yoshimura N: Verteporfin PDT for non-standard indications--a review of current literature. Graefes Arch Clin Exp Ophthalmol. 2010 May;248(5):613-26. doi: 10.1007/s00417-010-1307-z. Epub 2010 Feb 17.</citation>
      </article>
      <article>
        <ref-id>A692</ref-id>
        <pubmed-id>16945338</pubmed-id>
        <citation>Nowak-Sliwinska P, Karocki A, Elas M, Pawlak A, Stochel G, Urbanska K: Verteporfin, photofrin II, and merocyanine 540 as PDT photosensitizers against melanoma cells. Biochem Biophys Res Commun. 2006 Oct 20;349(2):549-55. Epub 2006 Aug 22.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.</indication>
  <pharmacodynamics>Verteporfin, otherwise known as benzoporphyrin derivative, is a medication used in conjunction with laser treatment to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels.</pharmacodynamics>
  <mechanism-of-action>Verteporfin is transported in the plasma primarily by lipoproteins. Once verteporfin is activated by light in the presence of oxygen, highly reactive, short-lived singlet oxygen and reactive oxygen radicals are generated. Light activation of verteporfin results in local damage to neovascular endothelium, resulting in vessel occlusion. Damaged endothelium is known to release procoagulant and vasoactive factors through the lipo-oxygenase (leukotriene) and cyclo-oxygenase (eicosanoids such as thromboxane) pathways, resulting in platelet aggregation, fibrin clot formation and vasoconstriction. Verteporfin appears to somewhat preferentially accumulate in neovasculature, including choroidal neovasculature. However, animal models indicate that the drug is also present in the retina. As singlet oxygen and reactive oxygen radicals are cytotoxic, Verteporfin can also be used to destroy tumor cells.</mechanism-of-action>
  <toxicity>Overdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.</toxicity>
  <metabolism>Metabolized to a small extent to its diacid metabolite by liver and plasma esterases. NADPH-dependent liver enzyme systems (including the cytochrome P450 isozymes) do not appear to play a role in the metabolism of verteporfin.</metabolism>
  <absorption/>
  <half-life>Following intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.</half-life>
  <protein-binding/>
  <route-of-elimination>Elimination is by the fecal route, with less than 0.01% of the dose recovered in urine.</route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <salts/>
  <synonyms>
    <synonym language="english/german" coder="inn/usan">Verteporfin</synonym>
    <synonym language="spanish" coder="inn">Verteporfina</synonym>
    <synonym language="french" coder="inn">Vertéporfine</synonym>
    <synonym language="latin" coder="inn">Verteporfinum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Visudyne</name>
      <labeller>QLT Ophthalmics, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50236-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>15 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021119</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visudyne</name>
      <labeller>Novartis</labeller>
      <ndc-id/>
      <ndc-product-code>0078-0437</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-14</started-marketing-on>
      <ended-marketing-on>2012-09-01</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>2 mg/1mL</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021119</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visudyne</name>
      <labeller>Valeant Pharmaceuticals North America LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0187-5600</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength>15 mg/1</strength>
      <route>Intravenous</route>
      <fda-application-number>NDA021119</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Visudyne</name>
      <labeller>Valeant Canada Lp Valeant Canada S.E.C.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02242367</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-06-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Powder, for solution</dosage-form>
      <strength>15 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Visudine</name>
      <company>Novartis</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Visudyne</name>
      <ingredients>Verteporfin</ingredients>
    </mixture>
    <mixture>
      <name>Visudyne</name>
      <ingredients>Verteporfin</ingredients>
    </mixture>
    <mixture>
      <name>Visudyne</name>
      <ingredients>Verteporfin</ingredients>
    </mixture>
    <mixture>
      <name>Visudyne</name>
      <ingredients>Verteporfin</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Hollister-Stier Laboratories LLC</name>
      <url>http://www.hollisterstier.com</url>
    </packager>
    <packager>
      <name>JHP Pharmaceuticals LLC</name>
      <url>http://www.jhppharma.com</url>
    </packager>
    <packager>
      <name>Novartis AG</name>
      <url>http://www.novartis.com</url>
    </packager>
    <packager>
      <name>QLT Inc.</name>
      <url>http://www.qltinc.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Qlt inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Visudyne 15 mg vial</description>
      <cost currency="USD">1702.64</cost>
      <unit>vial</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Antineovascularisation Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Biological Factors</category>
      <mesh-id>D001685</mesh-id>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>EENT Drugs, Miscellaneous</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Ocular Vascular Disorder Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Photoabsorption</category>
      <mesh-id/>
    </category>
    <category>
      <category>Photoenhancer</category>
      <mesh-id/>
    </category>
    <category>
      <category>Photosensitizing Activity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Photosensitizing Agents</category>
      <mesh-id>D017319</mesh-id>
    </category>
    <category>
      <category>Pigments, Biological</category>
      <mesh-id>D010860</mesh-id>
    </category>
    <category>
      <category>Porphyrins</category>
      <mesh-id>D011166</mesh-id>
    </category>
    <category>
      <category>Radiation-Sensitizing Agents</category>
      <mesh-id>D011838</mesh-id>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>15 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength>2 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Powder, for solution</form>
      <route>Intravenous</route>
      <strength>15 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="S01LA01">
      <level code="S01LA">Antineovascularisation agents</level>
      <level code="S01L">OCULAR VASCULAR DISORDER AGENTS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00460.pdf?1265922810</fda-label>
  <patents>
    <patent>
      <number>5214036</number>
      <country>United States</country>
      <approved>1993-05-25</approved>
      <expires>2010-05-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2536069</number>
      <country>Canada</country>
      <approved>2008-06-03</approved>
      <expires>2014-03-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>1339927</number>
      <country>Canada</country>
      <approved>1998-06-23</approved>
      <expires>2015-06-23</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5756541</number>
      <country>United States</country>
      <approved>1998-05-26</approved>
      <expires>2016-03-11</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5798349</number>
      <country>United States</country>
      <approved>1998-08-25</approved>
      <expires>2015-08-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5707608</number>
      <country>United States</country>
      <approved>1998-01-13</approved>
      <expires>2015-08-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00707</drugbank-id>
      <name>Porfimer sodium</name>
      <description>Verteporfin may increase the photosensitizing activities of Porfimer sodium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00140</drugbank-id>
      <name>Riboflavin</name>
      <description>Riboflavin may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00553</drugbank-id>
      <name>Methoxsalen</name>
      <description>Methoxsalen may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>Carprofen may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00855</drugbank-id>
      <name>Aminolevulinic acid</name>
      <description>Aminolevulinic acid may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>Tiaprofenic acid may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02285</drugbank-id>
      <name>Protoporphyrin</name>
      <description>Protoporphyrin may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04571</drugbank-id>
      <name>Trioxsalen</name>
      <description>Trioxsalen may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04619</drugbank-id>
      <name>Acetophenone</name>
      <description>Acetophenone may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05296</drugbank-id>
      <name>Motexafin lutetium</name>
      <description>Motexafin lutetium may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05428</drugbank-id>
      <name>Motexafin gadolinium</name>
      <description>Motexafin gadolinium may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06261</drugbank-id>
      <name>Hexaminolevulinate</name>
      <description>Hexaminolevulinate may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06659</drugbank-id>
      <name>Rostaporfin</name>
      <description>Rostaporfin may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>Cyamemazine may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11630</drugbank-id>
      <name>Temoporfin</name>
      <description>Temoporfin may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11812</drugbank-id>
      <name>Talaporfin</name>
      <description>Talaporfin may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12216</drugbank-id>
      <name>Bergapten</name>
      <description>Bergapten may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15351</drugbank-id>
      <name>Dihematoporphyrin ether</name>
      <description>Dihematoporphyrin ether may increase the photosensitizing activities of Verteporfin.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.02</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.7</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.36e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>6.34</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>3-[(23S,24R)-14-ethenyl-5-(3-methoxy-3-oxopropyl)-22,23-bis(methoxycarbonyl)-4,10,15,24-tetramethyl-25,26,27,28-tetraazahexacyclo[16.6.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶.0¹⁹,²⁴]octacosa-1,3,5,7,9,11(27),12,14,16,18(25),19,21-dodecaen-9-yl]propanoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>VERT</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>718.7942</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>718.30026434</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC(=O)CCC1=C2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(CCC(O)=O)=C5C)C(C=C)=C4C)C2=CC=C([C@@H](C(=O)OC)[C@@]32C)C(=O)OC)=C1C</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C41H42N4O8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C41H42N4O8/c1-9-23-20(2)29-17-34-27-13-10-26(39(49)52-7)38(40(50)53-8)41(27,5)35(45-34)19-30-22(4)25(12-15-37(48)51-6)33(44-30)18-32-24(11-14-36(46)47)21(3)28(43-32)16-31(23)42-29/h9-10,13,16-19,38,42,44H,1,11-12,14-15H2,2-8H3,(H,46,47)/b28-16-,29-17-,30-19-,31-16-,32-18-,33-18-,34-17-,35-19-/t38-,41+/m0/s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>YTZALCGQUPRCGW-MXVXOLGGSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>173.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>199.08</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>81.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>4.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>4.78</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>logP</kind>
      <value>2.1</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>11996</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>5362420</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46506236</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01162</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4515032</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA451871</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Verteporfin</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL2052016</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/verteporfin.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/verteporfin.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>